OrphoMed

OrphoMed is a clinical stage biotechnology company focused on the development of best-in-class therapies for the treatment of inadequately-controlled gastrointestinal disorders. The company’s strategy is to take molecules that have proven mechanisms of action and to engineer improved pharmacological properties via a proprietary platform technology. OrphoMed’s lead program is aimed at treating irritable bowel syndrome with diarrhea (IBS-D), a seriously debilitating disorder that affects the intestinal tract. IBS-D has no identifiable cause and represents an important unmet medical need.

OrphoMed

San Francisco, CA

Website

04.25.2018
FDA Grants Fast Track Designation for OrphoMed’s ORP-101 fo…

Read More

05.24.2017
New Pappas Capital Fund Makes First Investment

Read More